KDR and breast carcinoma: Similarly, Zhang et al. [49] found that AT-533, an Hsp90 inhibitor, impairs breast cancer growth and angiogenesis by inhibiting the HIF-1α/VEGF/VEGFR-2 and AKT/mTOR pathways in HUVECs.